Insulet Co. (NASDAQ:PODD) Receives Consensus Rating of "Moderate Buy" from Analysts

Insulet Co. (NASDAQ:PODD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $277.13.

PODD has been the subject of several research analyst reports. Wells Fargo & Company upped their price target on shares of Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price objective for the company. Canaccord Genuity Group increased their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a report on Monday, December 9th. Citigroup increased their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Finally, BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a report on Friday, November 8th.

Insulet Price Performance

Shares of PODD traded up $2.62 during mid-day trading on Friday, hitting $285.70. 133,346 shares of the company were exchanged, compared to its average volume of 514,187. Insulet has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a 50 day moving average of $270.27 and a 200-day moving average of $241.58. The stock has a market cap of $20.04 billion, a price-to-earnings ratio of 48.91, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. During the same quarter in the prior year, the firm earned $0.71 EPS. Analysts expect that Insulet will post 3.22 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company's stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insulet

Several institutional investors have recently modified their holdings of the business. Globeflex Capital L P acquired a new position in shares of Insulet in the fourth quarter worth $131,000. Natixis Advisors LLC grew its stake in shares of Insulet by 33.8% in the fourth quarter. Natixis Advisors LLC now owns 44,371 shares of the medical instruments supplier's stock worth $11,584,000 after acquiring an additional 11,210 shares in the last quarter. Frank Rimerman Advisors LLC purchased a new stake in shares of Insulet during the 4th quarter worth $220,000. Commonwealth Equity Services LLC lifted its position in shares of Insulet by 3.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 16,665 shares of the medical instruments supplier's stock worth $4,351,000 after purchasing an additional 508 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its position in shares of Insulet by 203.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 44,875 shares of the medical instruments supplier's stock worth $11,820,000 after purchasing an additional 30,102 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.